This invention relates generally to Transcutaneous Electrical Nerve Stimulation (TENS) devices that deliver electrical currents across the intact skin of a user via electrodes so as to provide symptomatic relief of chronic pain, and more particularly to the measurement of the “on-skin” time of the TENS device in order to minimize skin irritation due to excessive uninterrupted wearing of the TENS device and to profile TENS therapy patterns.
Transcutaneous Electrical Nerve Stimulation (TENS) devices apply electrical currents to a particular area of the human body in order to suppress pain. The most common form of TENS is commonly referred to as “conventional TENS”. In conventional TENS, electrodes are placed on the user's skin within, or adjacent to, or proximal to, the area of pain. An electrical circuit generates stimulation pulses with specified characteristics. One or more pairs of electrodes, placed on the user's skin, transduce the electrical pulses and thereby stimulate underlying nerves in order to relieve pain. TENS electrodes typically utilize hydrogels to create a stable low-impedance electrode-skin interface to facilitate the delivery of electrical current to the user so as to stimulate peripheral sensory nerves. Close contact of the electrode (both gel pads and backing materials) with the skin of the user creates a temporary barrier that limits the covered skin area from being exposed to the air.
Pain relief from TENS stimulation usually begins within 15 minutes of the stimulation onset and may last up to an hour following the completion of the stimulation period (also known as a “therapy session”). Each therapy session typically runs for 30-60 minutes. To maintain pain relief (i.e., hypoalgesia), TENS therapy sessions typically need to be initiated at regular intervals. Newly developed wearable TENS devices such as the QUELL™ system developed by Neurometrix, Inc. of Waltham, Mass., USA provide users with an option to automatically restart therapy sessions at pre-determined time intervals.
The convenience of “wear-and-forget” TENS technology may lead some users to wear the TENS device for an extended period of time without removing the device from the contacted skin area. Covering the skin area with a TENS device for an extended period of time may cause skin irritation for the user. It is therefore important to monitor the “on-skin” time duration of the TENS device and, where the “on-skin” time duration exceeds a limit, to provide the user with feedback and a reminder (prompt) to “air-out” the skin under the device (i.e., by temporarily removing the TENS device from the user's skin).
The present invention comprises the provision and use of a novel TENS device which consists of a stimulator designed to be placed on a user's upper calf (or other anatomical location) and a pre-configured electrode array designed to provide circumferential stimulation in the area of the user's upper calf (or other anatomical location). A key feature of the present invention is that the TENS device is adapted to measure the on-skin time of the TENS device. When the on-skin time exceeds a threshold value, feedback and a reminder (prompt) are provided to the user as a reminder to remove the TENS device from the covered skin area in order to allow the skin area to “air-out”. Regularly airing-out covered skin areas is an effective means to minimize skin irritation, which is the most frequently reported side effect of TENS therapy.
In one preferred form of the present invention, there is provided apparatus for providing transcutaneous electrical nerve stimulation (TENS) therapy to a user, said apparatus comprising:
a stimulation unit for electrically stimulating at least one nerve of the user;
an electrode array connectable to said stimulation unit, said electrode array comprising a plurality of electrodes for electrical stimulation of the at least one nerve of the user;
a monitoring unit electrically connected to said stimulation unit for monitoring the on-skin status of said electrode array;
an analysis unit for analyzing said on-skin status of said electrode array to determine the effective on-skin time of said electrode array; and a feedback unit for alerting the user when said analysis unit determines that the effective on-skin time exceeds a threshold.
In another preferred form of the present invention, there is provided a method for monitoring the on-skin time of a transcutaneous electrical nerve stimulation (TENS) device for providing TENS therapy to at least one nerve of a user through an electrode array, said method comprising the steps of:
applying the electrode array to the surface of the user's skin to provide electrical contact between the electrode array and the skin of the user;
electrically stimulating said at least one nerve of the user with an electrical stimulator connected to the electrode array;
monitoring the on-skin status of the electrode array;
analyzing the on-skin status of the electrode array to determine the effective on-skin time; and alerting the user of the effective on-skin time.
These and other objects and features of the present invention will be more fully disclosed or rendered obvious by the following detailed description of the preferred embodiments of the invention, which is to be considered together with the accompanying drawings wherein like numbers refer to like parts, and further wherein:
TENS device 100 is shown in greater detail in
Still looking at
The preferred embodiment of the invention is designed to be worn on the user's upper calf 140 as shown in
Electrical current (i.e., for therapeutic electrical stimulation to the tissue) is provided to the electrode pairs 154, 156 and 152, 158 by connectors 160, 162 which mate with complementary connectors 210, 212, respectively, on stimulator 105 (see
In one preferred embodiment of the present invention, the skin-contacting conductive material of electrodes 152, 154, 156, 158 is a hydrogel material which is “built into” electrodes 152, 154, 156, 158. The function of the hydrogel material on the electrodes is to serve as an interface between the electrodes 152, 154, 156, 158 and the skin of the user (i.e., within, or adjacent to, or proximal to, the portion of the user's body in which the sensory nerves which are to be stimulated reside). Other types of electrodes such as dry electrodes and non-contact stimulation electrodes have also been contemplated and are considered to be within the scope of the present invention.
Further details regarding the construction and use of the various aspects of TENS device 100 are disclosed in (1) pending prior U.S. patent application Ser. No. 14/610,757, filed Jan. 30, 2015 by NeuroMetrix, Inc. and Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION and the patent applications incorporated therein by reference; (2) pending prior U.S. patent application Ser. No. 14/230,648, filed Mar. 31, 2014 by Neurometrix, Inc. and Shai Gozani et al. for DETECTING CUTANEOUS ELECTRODE PEELING USING ELECTRODE-SKIN IMPEDANCE and the patent applications incorporated therein by reference; (3) pending prior U.S. patent application Ser. No. 14/253,628, filed Apr. 15, 2014 by Neurometrix, Inc. and Shai Gozani et al. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH AUTOMATIC DETECTION OF USER SLEEP-WAKE STATE and the patent applications incorporated therein by reference; and (4) pending prior U.S. patent application Ser. No. 14/269,887, filed May 5, 2014 by NeuroMetrix, Inc. and Thomas Ferree et al. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH USER GESTURE DETECTOR AND ELECTRODE-SKIN CONTACT DETECTOR, WITH TRANSIENT MOTION DETECTOR FOR INCREASING THE ACCURACY OF THE SAME and the patent applications incorporated therein by reference; all of which foregoing patent applications are hereby incorporated herein by reference.
Wearing the TENS device for an extended period of time without removing the TENS device from the contacted skin area may cause skin irritation for the user. It is therefore important to monitor the “on-skin” time duration of the TENS device and, where the “on-skin” time duration exceeds a limit, to provide the user with feedback and a reminder (prompt) to “air-out” the skin under the TENS device. By way of example but not limitation, this “airing-out” can be accomplished by removing the TENS device from the user's body altogether, or by repositioning the TENS device on the contralateral limb of the user, etc.
In view of the foregoing, the present invention comprises the provision and use of a novel TENS device which includes novel means to determine its on-skin time duration (e.g., the period of time over which the TENS device, including its electrodes, maintains constant, uninterrupted contact with the user's skin).
During a period when the TENS device is providing active therapy to the user, current pulses with an intensity and duration optimized for therapeutic purposes are delivered to the user through the electrode-skin interface created by the electrodes placed on the skin and electrically connected to the stimulation circuitry of the TENS stimulator. During the therapy period, the presence or absence of electrode-skin contact (i.e., whether the TENS device is on-skin or off-skin) can be determined by measuring the stimulation current which is already flowing through the TENS device (i.e., so as to provide therapeutic nerve stimulation to the user).
More particularly, a preferred embodiment of the present invention is shown in
More particularly, when TENS device 100 is on the skin of the user, the equivalent circuit 280 shown in
On the other hand, when the TENS device is not on the skin of the user, the equivalent circuit 290 (
If the stimulating current Is is of a reasonable magnitude and cannot be sensed (i.e., if the output of amplifier 237 is effectively zero), one may conclude that no electrode-skin contact is occurring (i.e., that the TENS device is “off-skin”). Otherwise, the TENS device is considered to be on-skin and classifying unit 502 of monitoring unit 500 will “set a flag” indicative of the on-skin condition. Analysis unit 505 reads the flags set by classifying unit 502 and, using this information, determines the on-skin time duration of the therapy periods. When the on-skin time duration meets a predetermined threshold, analysis unit 505 causes feedback unit 510 (e.g., a vibration module) to provide an appropriate alert to the user.
Thus, monitoring unit 500 comprises an appropriately-programmed circuit module which identifies when the current sensing voltage output by amplifier 237 indicates the presence of an on-skin condition for TENS device 100. The construction of the appropriately-programmed circuit module of monitoring unit 500 will be apparent to those skilled in the art in view of the present disclosure.
And classifying unit 502 comprises an appropriately-programmed circuit module which “sets a flag” indicative of the on-skin condition for TENS device 100. The construction of the appropriately-programmed circuit module of classifying unit 502 will be apparent to those skilled in the art in view of the present disclosure.
And analysis unit 505 comprises an appropriately-programmed circuit module which monitors the flags set by classifying unit 502 and determines the on-skin time duration for TENS device 100 during the therapy periods and, when the on-skin time meets a predetermined threshold, sends an alert instruction to feedback unit 510. The construction of the appropriately-programmed circuit module of analysis unit 505 will be apparent to those skilled in the art in view of the present disclosure.
And feedback unit 510 comprises an appropriately-programmed circuit module which, when it receives the alert instruction from analysis unit 505, appropriately alerts the user. The construction of the appropriately-programmed circuit module of feedback unit 510 will be apparent to those skilled in the art in view of the present disclosure.
Novel TENS device 100 is also provided with means to measure electrode-skin contact time when the TENS device is not actively providing TENS stimulation to the user, i.e., by providing means for monitoring the device's on-skin status during a non-therapy period. The ability to monitor the device's on-skin status under non-stimulation conditions is important, inasmuch as a user may wear the TENS device for a much longer period of time than the total stimulation time, which can result in excessive on-skin time.
A preferred embodiment of the present invention is shown in
More particularly, when TENS device 100 is on the skin of the user, the equivalent circuit 260 shown in
On the other hand, when TENS device 100 is not on the skin of the user, the equivalent circuit 270 (
Thus, where the cathode voltage measured from the amplifier 207 is non-zero and close to the anode voltage Va of voltage source 204, one may conclude that electrode-skin contact is occurring (i.e., that TENS device 100 is “on-skin”), and classifying unit 513 of monitoring unit 512 will “set a flag” indicative of the on-skin condition. Analysis unit 505 reads the flags set by classifying unit 513 and, using this information, determines the on-skin time duration of TENS device 100 during non-therapy periods. When the on-skin time meets a predetermined threshold, analysis unit 505 causes feedback unit 510 (e.g., a vibration module) to provide an appropriate alert to the user.
Thus, monitoring unit 512 comprises an appropriately-programmed circuit module which identifies when the cathode voltage output by amplifier 207 indicates the presence of an on-skin condition. The construction of the appropriately-programmed circuit module of monitoring unit 512 will be apparent to those skilled in the art in view of the present disclosure.
And classifying unit 513 comprises an appropriately-programmed circuit module which “sets a flag” indicative of the on-skin condition for TENS device 100. The construction of the appropriately-programmed circuit module of classifying unit 513 will be apparent to those skilled in the art in view of the present disclosure.
And analysis unit 505 comprises an appropriately-programmed circuit module which monitors the flags set by classifying unit 513 and determines the on-skin time duration for TENS device 100 during the non-therapy periods and, when the on-skin time meets a predetermined threshold, sends an alert instruction to feedback unit 510. The construction of the appropriately-programmed circuit module of analysis unit 505 will be apparent to those skilled in the art in view of the present disclosure.
And feedback unit 510 comprises an appropriately-programmed circuit module which, when it receives the alert instruction from analysis unit 505, appropriately alerts the user. The construction of the appropriately-programmed circuit module of feedback unit 510 will be apparent to those skilled in the art in view of the present disclosure.
Thus it will be seen that TENS device 100 comprises two different cathode-side detection circuits (i.e., monitoring unit 500, including its classifying unit 502; and monitoring unit 512, including its classifying unit 513) to identify the on-skin status of the TENS device, depending on whether the TENS device is in its therapy mode or its non-therapy mode.
More particularly, when TENS device 100 is in its therapy mode, the cathode side detection circuit shown in
Furthermore, it will be appreciated that when TENS device 100 is in its non-therapy mode, the cathode side detection circuit shown in
It will be appreciated that TENS device 100 preferably includes automatic selection circuitry for determining whether the output of the cathode side detection circuit of
It will also be appreciated that analysis unit 505 of TENS device 100 is configured to use an aggregation of the outputs of monitoring unit 500 (including classifying unit 502) and monitoring unit 512 (including classifying unit 513) to determine the on-skin time duration of the TENS device, since TENS device 100 may be worn continuously across various therapy and non-therapy time periods. In other words, it is important that analysis unit 505 be reading the on-skin flags of both classifying unit 502 and classifying unit 513 so as to obtain an accurate measure of the total on-skin time duration of the TENS device.
Furthermore, it should be appreciated that analysis unit 505 may be configured to use various measures to identify a threshold on-skin time duration, e.g., analysis unit 505 may be configured to send an alert instruction to feedback unit 510 when the total constant, uninterrupted-contact on-skin time exceeds a predetermined number (e.g., when the total constant, uninterrupted-contact on-skin time exceeds 4 hours), or analysis unit 505 may be configured to send an alert instruction to feedback unit 510 when the total on-skin time within a given time period exceeds a predetermined number (e.g., when analysis unit 505 detects 8 hours of on-skin time within a time period of 10 hours), etc.
Again, analysis unit 505 comprises an appropriately-programmed circuit module configured to use an appropriate measure to identify a threshold on-skin time duration. The construction of the appropriately-programmed circuit module of analysis unit 505 will be apparent to those skilled in the art in view of the present disclosure.
To maintain a healthy skin condition, it is important for the skin area under the TENS device to be re-exposed to open air after a total on-skin time duration of the TENS device exceeds a threshold.
In one form of the present invention, TENS device 100 is configured so that when analysis unit 505 determines that the total on-skin time of the TENS device exceeds a threshold, the TENS device then provides feedback and a reminder (prompt) to the user using feedback unit 510, e.g., through electro-tactile feedback or other means.
The total on-skin time duration threshold can be set by the device manufacturer with a default value. The total on-skin time duration threshold can also be set by the user or by the recommendation of a healthcare provider based on the condition of the user (e.g., skin condition, age, gender, etc.). The total on-skin time duration threshold may also be different for daytime use and for nighttime use.
In another form of the present invention, analysis unit 505 of the TENS device is configured so that the “effective” on-skin time duration is used to determine when the TENS device should activate the reminder for the user (instead of using the “total on-skin time duration” to trigger the reminder for the user). Effective on-skin time can be just the total accumulated time in which the TENS device has been on-skin, either during a therapy period, a non-therapy period, or a combination of therapy and non-therapy periods. The effective on-skin time calculation can also assign a different (higher) weight to the time period in which stimulation is on-going during therapy in order to take into consideration an additional skin irritation effect caused by the TENS stimulating current. Further, the weight factor during the stimulation time period can be made to be proportional to the stimulation intensity. The effective on-skin time calculation can also use electrode-skin impedance as a weight factor to the time period in which the impedance is measured to account for various electrode-skin contact conditions, as well as adverse changes in skin conditions that are reflected in the impedance (such as a change in the electrode-skin capacitance due to inflammation).
The feedback to the user provided by feedback unit 510 can be the delivery of a sequence of electric stimulation pulses with a distinct pattern so that it will be recognized by the user as a signal to “air-out” the skin under the device. The pulse train can have a constant intensity or variable intensities with the aim to attract the user's attention. The feedback can be haptic perception via mechanical vibrations. The feedback can be disabled at night when the device determines that the user is asleep in order to avoid waking the user. The feedback can also be presented to an external device such as an application running on a nearby smartphone (preferably a smartphone which has been authenticated for secure communications with TENS device 100). Another means of feedback can be an alert to a caregiver of the user (e.g., via text message) if the user is unable to initiate the device removal action on his or her own.
The effective device on-skin time can also be used as a part of metrics to determine the TENS utilization profile of a given user. For example, the percentage of the on-skin time that is devoted to actual TENS stimulation may be indicative of the severity of the pain of the user, based on the assumption that the user would initiate a pain-relieving TENS stimulation session more often if the severity of the pain is higher.
It should be understood that many additional changes in the details, materials, steps and arrangements of parts, which have been herein described and illustrated in order to explain the nature of the present invention, may be made by those skilled in the art while still remaining within the principles and scope of the invention.
This patent application is a continuation of pending prior U.S. patent application Ser. No. 14/794,588, filed Jul. 8, 2015 by NeuroMetrix, Inc. for MEASURING THE “ON-SKIN” TIME OF A TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS) DEVICE IN ORDER TO MINIMIZE SKIN IRRITATION DUE TO EXCESSIVE UNINTERRUPTED WEARING OF THE SAME, which in turn: (1) is a continuation-in-part of prior U.S. patent application Ser. No. 14/610,757, filed Jan. 30, 2015 by NeuroMetrix, Inc. and Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, which patent application in turn: (A) is a continuation of prior U.S. patent application Ser. No. 13/678,221, filed Nov. 15, 2012 by NeuroMetrix, Inc. and Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, which in turn claims benefit of: (i) prior U.S. Provisional Patent Application Ser. No. 61/560,029, filed Nov. 15, 2011 by Shai N. Gozani for SENSUS OPERATING MODEL; and(ii) prior U.S. Provisional Patent Application Ser. No. 61/657,382, filed Jun. 8, 2012 by Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION; (2) is a continuation-in-part of pending prior U.S. patent application Ser. No. 14/269,887, filed May 5, 2014 by NeuroMetrix, Inc. and Thomas Ferree et al. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH USER GESTURE DETECTOR AND ELECTRODE-SKIN CONTACT DETECTOR, WITH TRANSIENT MOTION DETECTOR FOR INCREASING THE ACCURACY OF THE SAME, which patent application in turn: (A) is a continuation-in-part of prior U.S. patent application Ser. No. 14/230,648, filed Mar. 31, 2014 by Neurometrix, Inc. and Shai Gozani et al. for DETECTING CUTANEOUS ELECTRODE PEELING USING ELECTRODE-SKIN IMPEDANCE, which claims benefit of: (i) prior U.S. Provisional Patent Application Ser. No. 61/806,481, filed Mar. 29, 2013 by Shai Gozani for DETECTING ELECTRODE PEELING BY RELATIVE CHANGES IN SKIN-ELECTRODE IMPEDANCE;(B) is a continuation-in-part of pending prior U.S. patent application Ser. No. 14/253,628, filed Apr. 15, 2014 by Neurometrix, Inc. and Shai Gozani et al. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH AUTOMATIC DETECTION OF USER SLEEP-WAKE STATE, which claims benefit of: (i) prior U.S. Provisional Patent Application Ser. No. 61/811,864, filed Apr. 15, 2013 by Shai Gozani for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR WITH AUTOMATIC DETECTION OF PATIENT SLEEP-WAKE STATE;(C) claims benefit of prior U.S. Provisional Patent Application Ser. No. 61/819,159, filed May 3, 2013 by Neurometrix, Inc. and Thomas Ferree et al. for TAP DETECTOR WITH HIGH SENSITIVITY AND SPECIFICITY FOR A WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR; and(D) claims benefit of prior U.S. Provisional Patent Application Ser. No. 61/858,150, filed Jul. 25, 2013 by Neurometrix, Inc. and Andres Aguirre et al. for MOVEMENT REGULATED TRIP CONDITIONS IN A WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR; and (3) claims benefit of prior U.S. Provisional Patent Application Ser. No. 62/021,807, filed Jul. 8, 2014 by Neurometrix, Inc. and Xuan Kong et al. for MEASURING TENS DEVICE ON-SKIN TIME TO PREVENT AND MINIMIZE SKIN IRRITATION. The thirteen (13) above-identified patent applications are hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1741962 | Theodoropulos | Dec 1929 | A |
D263869 | Sumiyasu | Apr 1982 | S |
4503863 | Katims | Mar 1985 | A |
4605010 | McEwen | Aug 1986 | A |
4738250 | Fulkerson et al. | Apr 1988 | A |
5063929 | Bartelt et al. | Nov 1991 | A |
5121747 | Andrews | Jun 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
D346029 | Shalvi | Apr 1994 | S |
5350414 | Kolen | Sep 1994 | A |
5429589 | Cartmell et al. | Jul 1995 | A |
5479939 | Ogino | Jan 1996 | A |
5487759 | Bastyr et al. | Jan 1996 | A |
5562718 | Palermo | Oct 1996 | A |
5806522 | Katims | Sep 1998 | A |
D411887 | Agarwala | Jul 1999 | S |
5948000 | Larsen et al. | Sep 1999 | A |
6099488 | Hung | Aug 2000 | A |
6161044 | Silverstone | Dec 2000 | A |
6266558 | Gozani et al. | Jul 2001 | B1 |
D450313 | Koinuma | Nov 2001 | S |
6430450 | Bach-y-Rita et al. | Aug 2002 | B1 |
D462772 | Lamping et al. | Sep 2002 | S |
6456884 | Kenney | Sep 2002 | B1 |
6662051 | Eraker et al. | Dec 2003 | B1 |
D541042 | Andre et al. | Apr 2007 | S |
D566383 | Harris et al. | Apr 2008 | S |
D592200 | Liu | May 2009 | S |
D598556 | Chen | Aug 2009 | S |
D607198 | Andre et al. | Jan 2010 | S |
7668598 | Herregraven et al. | Feb 2010 | B2 |
D611611 | Sachi et al. | Mar 2010 | S |
D615526 | Andre et al. | May 2010 | S |
7720548 | King | May 2010 | B2 |
7725193 | Chu | May 2010 | B1 |
7787946 | Stahmann et al. | Aug 2010 | B2 |
D625829 | Arbesman et al. | Oct 2010 | S |
D629115 | Robertson | Dec 2010 | S |
D636881 | Clemens et al. | Apr 2011 | S |
D637988 | Jinkinson | May 2011 | S |
8108049 | King | Jan 2012 | B2 |
8121702 | King | Feb 2012 | B2 |
8131374 | Moore et al. | Mar 2012 | B2 |
D658302 | Nixon | Apr 2012 | S |
D680735 | Itabashi et al. | Apr 2013 | S |
8421642 | McIntosh et al. | Apr 2013 | B1 |
D688707 | Vincent et al. | Aug 2013 | S |
D705428 | Cheney et al. | May 2014 | S |
D712045 | Thornton | Aug 2014 | S |
8825175 | King | Sep 2014 | B2 |
8862238 | Rahimi et al. | Oct 2014 | B2 |
D716963 | Yosef et al. | Nov 2014 | S |
8948876 | Gozani et al. | Feb 2015 | B2 |
D732682 | Porat | Jun 2015 | S |
9168375 | Rahimi et al. | Oct 2015 | B2 |
D744661 | Rizzi | Dec 2015 | S |
D750263 | Shigeno et al. | Feb 2016 | S |
D750798 | Yosef et al. | Mar 2016 | S |
D754973 | Danze et al. | May 2016 | S |
D757292 | Chen | May 2016 | S |
D758605 | Chen | Jun 2016 | S |
D758606 | Chen | Jun 2016 | S |
D759262 | Chen | Jun 2016 | S |
D759263 | Chen | Jun 2016 | S |
D759958 | Requa | Jun 2016 | S |
D762628 | Yoon et al. | Aug 2016 | S |
D762872 | Chen | Aug 2016 | S |
D767775 | Gilmer et al. | Sep 2016 | S |
9452287 | Rosenbluth et al. | Sep 2016 | B2 |
9474898 | Gozani et al. | Oct 2016 | B2 |
D774654 | Anderson | Dec 2016 | S |
D778453 | Knaus et al. | Feb 2017 | S |
D779677 | Chen | Feb 2017 | S |
9561397 | Zaki | Feb 2017 | B2 |
D784544 | Dudkiewicz et al. | Apr 2017 | S |
D784546 | Gordon | Apr 2017 | S |
D784946 | Jun et al. | Apr 2017 | S |
D788056 | Choi et al. | May 2017 | S |
9656070 | Gozani et al. | May 2017 | B2 |
D789546 | Matfus et al. | Jun 2017 | S |
D789547 | Matfus et al. | Jun 2017 | S |
D791333 | Wilson | Jul 2017 | S |
D792363 | Kim et al. | Jul 2017 | S |
D794331 | Grote | Aug 2017 | S |
9731126 | Ferree et al. | Aug 2017 | B2 |
D801542 | Anderson | Oct 2017 | S |
D802780 | Hsu | Nov 2017 | S |
D806669 | Kangasmaa et al. | Jan 2018 | S |
D810843 | Karvandi | Feb 2018 | S |
D811729 | Bysshe | Mar 2018 | S |
D813407 | Chen | Mar 2018 | S |
D813408 | Chen | Mar 2018 | S |
D828569 | Mercuro | Sep 2018 | S |
D829182 | Li | Sep 2018 | S |
D830565 | Xu | Oct 2018 | S |
D831017 | Choe et al. | Oct 2018 | S |
D831221 | Smith | Oct 2018 | S |
D831335 | Crease | Oct 2018 | S |
D832230 | Lee et al. | Oct 2018 | S |
20020010497 | Merfeld et al. | Jan 2002 | A1 |
20030023192 | Foxlin | Jan 2003 | A1 |
20030074037 | Moore | Apr 2003 | A1 |
20030114892 | Nathan et al. | Jun 2003 | A1 |
20030208246 | Kotlik et al. | Nov 2003 | A1 |
20040122483 | Nathan et al. | Jun 2004 | A1 |
20050059903 | Izumi | Mar 2005 | A1 |
20050080463 | Slahmann et al. | Apr 2005 | A1 |
20060052788 | Thelen et al. | Mar 2006 | A1 |
20060085049 | Cory et al. | Apr 2006 | A1 |
20060095088 | De Ridder | May 2006 | A1 |
20060173507 | Mrva et al. | Aug 2006 | A1 |
20060190057 | Reese | Aug 2006 | A1 |
20070060922 | Dreyfuss | Mar 2007 | A1 |
20070276449 | Gunter et al. | Nov 2007 | A1 |
20080077192 | Harry et al. | Mar 2008 | A1 |
20080146980 | Rousso et al. | Jun 2008 | A1 |
20080147143 | Popovic et al. | Jun 2008 | A1 |
20080147146 | Wahlgren et al. | Jun 2008 | A1 |
20080312709 | Volpe et al. | Dec 2008 | A1 |
20090030476 | Hargrove | Jan 2009 | A1 |
20090112214 | Philippon et al. | Apr 2009 | A1 |
20090131993 | Rousso et al. | May 2009 | A1 |
20090240303 | Wahlstrand et al. | Sep 2009 | A1 |
20090264789 | Molnar et al. | Oct 2009 | A1 |
20090270947 | Stone et al. | Oct 2009 | A1 |
20090326604 | Tyler | Dec 2009 | A1 |
20100004715 | Fahey | Jan 2010 | A1 |
20100042180 | Mueller et al. | Feb 2010 | A1 |
20100057149 | Fahey | Mar 2010 | A1 |
20100087903 | Van Herk et al. | Apr 2010 | A1 |
20100094103 | Kaplan et al. | Apr 2010 | A1 |
20100114257 | Torgerson | May 2010 | A1 |
20100131028 | Hsu | May 2010 | A1 |
20100198124 | Bhugra | Aug 2010 | A1 |
20100217349 | Fahey | Aug 2010 | A1 |
20100241464 | Amigo et al. | Sep 2010 | A1 |
20110066209 | Bodlaender et al. | Mar 2011 | A1 |
20110224665 | Crosby et al. | Sep 2011 | A1 |
20110257468 | Oser et al. | Oct 2011 | A1 |
20110264171 | Torgerson | Oct 2011 | A1 |
20110276107 | Simon | Nov 2011 | A1 |
20110282164 | Yang et al. | Nov 2011 | A1 |
20120010680 | Wei et al. | Jan 2012 | A1 |
20120108998 | Molnar et al. | May 2012 | A1 |
20130096641 | Strother et al. | Apr 2013 | A1 |
20130158627 | Gozani et al. | Jun 2013 | A1 |
20130217998 | Mahfouz et al. | Aug 2013 | A1 |
20140039450 | Green et al. | Feb 2014 | A1 |
20140057232 | Wetmore et al. | Feb 2014 | A1 |
20140081353 | Cook | Mar 2014 | A1 |
20140107729 | Sumners | Apr 2014 | A1 |
20140163444 | Ingvarsson et al. | Jun 2014 | A1 |
20140245791 | Proud et al. | Sep 2014 | A1 |
20140276549 | Osorio | Sep 2014 | A1 |
20140296934 | Gozani et al. | Oct 2014 | A1 |
20140296935 | Ferree et al. | Oct 2014 | A1 |
20140309709 | Gozani | Oct 2014 | A1 |
20140336730 | Simon et al. | Nov 2014 | A1 |
20140379045 | Rahimi et al. | Dec 2014 | A1 |
20150045853 | Alataris et al. | Feb 2015 | A1 |
20150174402 | Thomas et al. | Jun 2015 | A1 |
20150321000 | Rosenbluth | Nov 2015 | A1 |
20150328467 | Demers et al. | Nov 2015 | A1 |
20150335288 | Toth et al. | Nov 2015 | A1 |
20160367823 | Cowan et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
1919139 | Feb 2007 | CN |
101626804 | Jan 2010 | CN |
102355847 | Feb 2012 | CN |
102740919 | Oct 2012 | CN |
102010052710 | May 2012 | DE |
61-171943 | Oct 1986 | JP |
4-347140 | Dec 1992 | JP |
9-117453 | May 1997 | JP |
2000-167067 | Jun 2000 | JP |
2005-34402 | Feb 2005 | JP |
2006-68300 | Mar 2006 | JP |
4185846 | Sep 2008 | JP |
WO 9742999 | Nov 1997 | WO |
WO 9964105 | Dec 1999 | WO |
WO 2003051453 | Jun 2003 | WO |
WO 2004078132 | Sep 2004 | WO |
WO 2007061746 | May 2007 | WO |
WO 2008079757 | Jul 2008 | WO |
WO 2008088985 | Jul 2008 | WO |
WO 2011075179 | Jun 2011 | WO |
WO 2011137193 | Nov 2011 | WO |
WO 2012116407 | Sep 2012 | WO |
Entry |
---|
Ancoli-Israel, S. et al., The Role of Actigraphy in the Study of Sleep and Circadian Rhythms, Sleep, 2003, 26(3), p. 342-392. |
Barbarisi, Manlio et al., Pregabalin and Transcutaneous Electrical Nerve Stimulation for Postherpetic Neuralgia Treatment, The Clinical Journal of Pain, Sep. 2010;26(7):567-572. |
Bjordal JM et al., Transcutaneous electrical nerve stimulation (TENS) can reduce postoperative analgesic consumption. A meta-analysis with assessment of optimal treatment parameters for postoperative pain, European Journal of Pain, 2003, vol. 7(2): 181-188. |
Bloodworth DM et al., Comparison of stochastic vs. conventional transcutaneous electrical stimulation for pain modulation in patients with electromyographically documented radiculopathy. American Journal of Physical Medicine & Rehabilitation, 2004, vol. 83(8): 584-591. |
Chandran P et al., Development of opioid tolerance with repeated transcutaneous electrical nerve stimulation administration, Pain, 2003, vol. 102: 195-201. |
Chen CC et al., A comparison of transcutaneous electrical nerve stimulation (TENS) at 3 and 80 pulses per second on cold-pressor pain in healthy human participants, Clinical Physiology and Functioning Imaging, 2010, vol. 30(4): 260-268. |
Chen CC et al., An investigation into the effects of frequency-modulated transcutaneous electrical nerve stimulation (TENS) on experimentally-induced pressure pain in healthy human participants, The Journal of Pain, 2009, vol. 10(10): 1029-1037. |
Chen CC et al., Differential frequency effects of strong nonpainful transcutaneous electrical nerve stimulation on experimentally induced ischemic pain in healthy human participants, The Clinical Journal of Pain, 2011, vol. 27(5): 434-441. |
Chen CC et al., Does the pulse frequency of transcutaneous electrical nerve stimulation (TENS) influence hypoalgesia? A systematic review of studies using experimental pain and healthy human participants, Physiotherapy, 2008, vol. 94: 11-20. |
Claydon LS et al., Dose-specific effects of transcutaneous electrical nerve stimulation on experimental pain, Clinical Journal of Pain, 2011, vol. 27(7): 635-647. |
Cole, R.J. et al., Automatic Sleep/Wake Identification From Wrist Activity, Sleep, 1992, 15(5), p. 461-469. |
Cruccu G. et al., EFNS guidelines on neurostimulation therapy for neuropathic pain, European Journal of Neurology, 2007, vol. 14: 952-970. |
Davies HTO et al., Diminishing returns or appropriate treatment strategy?—an analysis of short-term outcomes after pain clinic treatment, Pain, 1997, vol. 70: 203-208. |
Desantana JM et al., Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain, Curr Rheumatol Rep. 2008, vol. 10(6): 492-499. |
Dubinsky RM et al., Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurology, Neurology, 2010, vol. 74: 173-176. |
Fary RE et al., Monophasic electrical stimulation produces high rates of adverse skin reactions in healthy subjects, Physiotherapy Theory and Practice, 2011, vol. 27(3): 246-251. |
Fishbain, David A. et al. Does Pain Mediate the Pain Interference with Sleep Problem in Chronic Pain? Findings from Studies for Management of Diabetic Peripheral Neuropathic Pain with Duloxetine, Journal of Pain Symptom Management, Dec. 2008;36(6):639-647. |
Fishbain, David A. et al., Transcutaneous Electrical Nerve Stimulation (TENS) Treatment Outcome in Long-Term Users, The Clinical Journal of Pain, Sep. 1996;12(3).201-214. |
Food and Drug Administration, Draft Guidance for Industry and Staff: Class II Special Controls Guidance Document: Transcutaneous Electrical Nerve Stimulator for Pain Relief, Apr. 5, 2010. |
Garrison DW et al., Decreased activity of spontaneous and noxiously evoked dorsal horn cells during transcutaneous electrical nerve stimulation (TENS), Pain, 1994, vol. 58: 309-315. |
Gilron, I. et al., Chronobiological Characteristics of Neuropathic Pain: Clinical Predictors of Diurnal Pain Rhythmicity, The Clinical Journal of Pain, 2013. |
Hori, T. et al., Skin Potential Activities and Their Regional Differences During Normal Sleep in Humans, The Japanese Journal of Physiology, 1970, vol. 20, p. 657-671. |
Jelinek HF et al., Electric pulse frequency and magnitude of perceived sensation during electrocutaneous forearm stimulation, Arch Phys Med Rehabil, 2010, vol. 91: 1372-1382. |
Jin DM et al., Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials, Diabetes Research and Clinical Practice, 2010, vol. 89: 10-15. |
Johnson MI et al., Analgesic effects of different frequencies of transcutaneous electrical nerve stimulation on cold-induced pain in normal subjects, Pain, 1989, vol. 39: 231-236. |
Johnson MI et al., Transcutaneous Electrical Nerve Stimulation (TENS) and TENS-like devices: do they provide pain relief?, Pain Reviews, 2001, vol. 8: 7-44. |
Johnson MI et al., Transcutaneous electrical nerve stimulation for the management of painful conditions: focus on neuropathic pain, Expert Review of Neurotherapeutics, 2011, vol. 11(5): 735-753. |
Johnson, M.I. et al., An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS). Implications for clinical use of TENS. Pain. Mar. 1991;44(3):221-229. |
Kaczmarek, Kurt A. et al.. Electrotactile and Vibrotactile Displays for Sensory Substitution Systems. IEEE Trans. Biomed. Eng. Jan. 1991;38 (1):1-16. |
Kantor G et al., The effects of selected stimulus waveforms on pulse and phase characteristics at sensory and motor thresholds, Physical Therapy, 1994, vol. 74(10): 951-962. |
Keller, Thierry et al., Electrodes for transcutaneous (surface) electrical stimulation, J. Automatic Control, University of Belgrade. 2008;18(2):35-45. |
Koumans, A. J. R. et al., Electrodermal Levels and Fluctuations During Normal Sleep, Psychophysiology, 1968, 5(3), p. 300-306. |
Kripke, D.F. et al., Wrist Actigraphic Scoring for Sleep Laboratory Patients: Algorithm Development, Journal of Sleep Research, 2010, 19(4), p. 612-619. |
Law PPW et al., Optimal stimulation frequency of transcutaneous electrical nerve stimulation on people with knee osteoarthritis, J Rehabil Med, 2004, vol. 36: 220-225. |
Leonard G et al., Deciphering the role of endogenous opioids in high-frequency TENS using low and high doses of naloxone, Pain, 2010, vol. 151: 215-219. |
Levy et al., A comparison of two methods for measuring thermal thresholds in diabetic neuropathy, Journal of Neurology, Neurosurgery, and Psychiatry, 1989, vol. 52: 1072-1077. |
Lykken, D.T., Properties of Electrodes Used in Electrodermal Measurement, J. Comp. Physiol. Psychol. Oct. 1959;52:629-634. |
Lykken, D.T., Square-Wave Analysis of Skin Impedance. Psychophysiology. Sep. 1970;7(2):262-275. |
Melzack R et al., Pain mechanisms: A New Theory, Science, 1965, vol. 150(3699): 971-979. |
Moran F et al., Hypoalgesia in response to transcutaneous electrical nerve stimulation (TENS) depends on stimulation intensity, The Journal of Pain, 2011, vol. 12(8): 929-935. |
Oosterhof, Jan et al., Outcome of transcutaneous electrical nerve stimulation in chronic pain: short-term results of a double-blind, randomised, placebo-controlled trial. J. Headache Pain. Sep. 2006;7(4):196-205. |
Oosterhof, Jan et al., The long-term outcome of transcutaneous electrical nerve stimulation in the treatment for patients with chronic pain: a randomized, placebo-controlled trial. Pain Pract. Sep. 2012;12(7):513-522. |
Pantaleao MA et al., Adjusting pulse amplitude during transcutaneous electrical nerve stimulation (TENS) application produces greater hypoalgesia, The Journal of Pain, 2011, vol. 12(5): 581-590. |
Paquet, J. et al., Wake Detection Capacity of Actigraphy During Sleep, Sleep, 2007, 30(10), p. 1362-1369. |
Pieber K et al., Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review, Journal of Rehabilitation Medicine, 2010, vol. 42: 289-295. |
Raskin, J. et al., A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain, Pain Medicine, 2005, 6(5), p. 346-356. |
Sadeh, A., The Role and Validity of Actigraphy in Sleep Medicine: An Update, Sleep Medicine Reviews, 2011, vol. 15, p. 259-267. |
Sadosky, A. et al., Burden of Illness Associated with Painful Diabetic Peripheral Neuropathy Among Adults Seeking Treatment in the US: Results from a Retrospective Chart Review and Cross-Sectional Survey, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, vol. 6. p. 79-92. |
Scherder, E. J. A. et al., Transcutaneous Electrical Nerve Stimulation (TENS) Improves the Rest-Activity Rhythm in Midstage Alzheimer's Disease, Behavioral Brain Research, 1999, vol. 101, p. 105-107. |
Tryon, W. W., Issues of Validity in Actigraphic Sleep Assessment, Sleep, 2004, 27(1), p. 158-165. |
Tsai, Y. et al., Impact of Subjective Sleep Quality on Glycemic Control in Type 2 Diabetes Mellitus, Family Practice, 2012, vol. 29, p. 30-35. |
Van Boxtel, A., Skin resistance during square-wave electrical pulses of 1 to 10 mA. Med. Biol. Eng. Comput. Nov. 1977;15(6):679-687. |
Van Someren, E. J. W. et al., Gravitational Artefact in Frequency Spectra of Movement Acceleration: Implications for Actigraphy in Young and Elderly Subjects, Journal of Neuroscience Methods, 1996, vol. 65, p. 55-62. |
Webster, J. B. et al., An Activity-Based Sleep Monitor System for Ambulatory Use, Sleep, 1982, 5(4), p. 389-399. |
Zelman, D. C. et al., Sleep Impairment in Patients With Painful Diabetic Peripheral Neuropathy, The Clinical Journal of Pain, 2006, 22(8), p. 681-685. |
Aurora, R. et al., The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults—An Update for 2012: Practice Parameters with an Evidence-Based Systematic Review and Meta-Analyses, Sleep, 2012, vol. 35, No. 8, p. 1039-1062. |
Bonnet, M, et al., Recording and Scoring Leg Movements, Sleep, 1993, vol. 16, No. 8, p. 748-759. |
Boyle, J. et al., Randomized, Placebo-Controlled Comparison of Amitriptyline, Duloxeline, and Pregabalin in Patients With Chronic Diabetic Peripheral Neuropathic Pain, Diabetes Care, 2012, vol. 35, p. 2451-2458. |
Kovacevic-Ristanovic, R, et al., Nonpharmacologic Treatment of Periodic Leg Movements in Sleep, Arch. Phys. Med. Rehabil., 1991, vol. 72, p. 385-389. |
Lopes, L. et al., Restless Legs Syndrome and Quality of Sleep in Type 2 Diabetes, Diabetes Care, 2005, vol. 28, No. 11, p. 2633-2636. |
Nightingale, S., The neuropathic pain market. Nature Reviews, 2012, vol. 11, p. 101-102. |
Zucconi, M. et al., The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG), Sleep Medicine, 2006, vol. 7, p. 175-183. |
Sheridan et al., Some Factors Influencing the Threshold of the Electrocutaneous Stimulus, Perceptual and Motor Skills, 1966, vol. 22, pp. 647-654. |
Number | Date | Country | |
---|---|---|---|
20170368345 A1 | Dec 2017 | US |
Number | Date | Country | |
---|---|---|---|
61560029 | Nov 2011 | US | |
61657382 | Jun 2012 | US | |
61806481 | Mar 2013 | US | |
61811864 | Apr 2013 | US | |
61819159 | May 2013 | US | |
61858150 | Jul 2013 | US | |
62021807 | Jul 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14794588 | Jul 2015 | US |
Child | 15621382 | US | |
Parent | 13678221 | Nov 2012 | US |
Child | 14610757 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14610757 | Jan 2015 | US |
Child | 14794588 | US | |
Parent | 14269887 | May 2014 | US |
Child | 14794588 | US | |
Parent | 14230648 | Mar 2014 | US |
Child | 14269887 | US | |
Parent | 14253628 | Apr 2014 | US |
Child | 14230648 | US |